Shoreview Elevates Garrett Davis to Principal Role

Shoreview Industries has promoted Garrett Davis to Principal in its business development group, the Minneapolis-based private equity firm announced Thursday. The move comes as Shoreview — which manages over $8 billion in assets — continues its aggressive push into behavioral health and specialty care services, sectors where deal flow has accelerated despite broader market volatility.

Davis joined Shoreview in 2021 as an Associate after stints at both Stifel Investment Banking and RSM, where he cut his teeth on middle-market M&A in healthcare and business services. His elevation to Principal after four years reflects the firm's pattern of promoting from within when someone consistently delivers on origination — something that's become harder to find as competition for healthcare assets intensifies.

The promotion also signals something less obvious: Shoreview's business development function is no longer just about finding deals. It's about thesis development. Davis and his colleagues aren't just sourcing targets; they're helping shape which subsectors Shoreview doubles down on next. In an environment where every healthcare-focused PE firm is chasing the same 200 high-quality platforms, that origination-strategy loop matters more than it used to.

Shoreview has deployed capital across 25 platforms since inception, with a deliberate focus on founder-led businesses in healthcare services and B2B software. But the real action lately has been in behavioral health — an area where regulatory tailwinds, reimbursement stability, and demographic demand are converging. Davis's deal experience in that space positions him to help Shoreview navigate what's become a crowded but still-growing arena.

Before Shoreview, Davis spent time in roles that gave him a front-row seat to the mechanics of middle-market dealmaking. At Stifel, he worked on M&A advisory for healthcare and business services companies — the kind of engagements where you learn how sellers think, what makes a deal fall apart, and which buyers actually close. That perspective is invaluable on the buy-side, where understanding the sell-side playbook can mean the difference between winning a process and coming in second.

His earlier experience at RSM, a major accounting and advisory firm, gave him exposure to valuation, due diligence, and the operational realities of companies pre-transaction. It's the kind of foundation that makes someone dangerous in business development — you're not just sourcing deals, you're pre-qualifying them through a lens that anticipates what diligence will uncover.

At Shoreview, Davis has been responsible for originating and evaluating investment opportunities primarily in healthcare services. That means he's been on the front lines of one of private equity's most competitive sectors, where deal multiples have stayed elevated even as financing costs have risen. The ability to source proprietary or lightly-shopped deals in that environment is rare — and promotable.

He's also been involved in portfolio support work, which at Shoreview means helping existing investments identify and execute add-on acquisitions. That dual mandate — new platform origination and portfolio growth — is increasingly common in middle-market PE, where firms realize that value creation depends as much on post-close execution as on entry valuation.

Shoreview isn't a generalist fund. It invests in two verticals: healthcare services and B2B software/tech-enabled services. Within healthcare, the firm has concentrated on subsectors where fragmentation creates roll-up opportunities, reimbursement is stable or improving, and unit economics can withstand labor cost inflation. Behavioral health checks all three boxes.

The firm's portfolio includes companies like Oasis Behavioral Health, a provider of inpatient psychiatric services, and RCA (Residential Center for Adults), which operates facilities for individuals with intellectual and developmental disabilities. These aren't the high-margin, capital-light tech assets that dominate venture portfolios. They're operationally intensive, heavily regulated, and dependent on a stable workforce — but they're also resilient, growing, and hard to disrupt.

Shoreview's model involves partnering with founder-led management teams and helping them professionalize operations, expand geographically, and execute buy-and-build strategies. That requires a business development function that can identify not just the initial platform but also the 5-10 add-ons that will come after. Davis's promotion suggests he's delivered on that — and that Shoreview expects him to do more of it.

The table above reflects Shoreview's deliberate vertical focus. Unlike mega-funds that can afford to spray capital across sectors, middle-market firms need domain expertise to win deals and create value. That expertise lives in people like Davis — investors who've spent years building relationships, understanding subsector nuances, and developing a gut sense for which opportunities are real versus which are broker-manufactured.

Behavioral health has become one of the most active subsectors in healthcare private equity, and for good reason. Demand is up — mental health awareness, destigmatization, and pandemic-era burnout have all contributed. Supply is constrained — there aren't enough psychiatrists, therapists, or inpatient beds to meet need. And reimbursement has improved, with both commercial payers and Medicaid expanding coverage for mental health and substance use disorder treatment.

Promotions at private equity firms are editorial decisions. They signal priorities, reward performance, and set cultural expectations for the rest of the team. Davis's elevation to Principal is a statement that business development — specifically, healthcare-focused origination — remains central to Shoreview's strategy.

It's also a retention move. Business development talent is mobile. Professionals who can consistently source high-quality deal flow get recruited aggressively, especially in healthcare where sector knowledge translates across firms. Promoting Davis keeps him in the fold and signals to junior team members that there's a clear path upward for those who deliver.

More broadly, the promotion suggests Shoreview is gearing up for continued deployment. Firms don't expand their origination leadership when they're in harvest mode. They do it when they're raising capital, when they see runway in their target sectors, and when they believe the next 12-24 months will present opportunities that require firepower to capture.

Shoreview declined to comment on whether Davis's promotion coincides with fundraising activity, but the timing is notable. Middle-market healthcare funds have continued to raise capital through 2024 and into 2025, even as venture funding has slowed and mega-buyouts have stalled. Limited partners still see healthcare services as a defensive, cash-generative sector worth backing — and firms like Shoreview benefit from that conviction.

There's also a competitive angle. Several healthcare-focused PE firms have recently added senior business development talent or promoted from within. The message across the industry is clear: proprietary deal flow is the differentiator. In a market where everyone has capital and everyone has an investment committee that can move quickly, the firm that sees the deal first — and has the relationship to win it — has the edge.

A decade ago, business development at a PE firm often meant cold-calling intermediaries and tracking auction processes. Today, it's more strategic. The best business development professionals are part originator, part sector analyst, part relationship manager. They're expected to develop theses, cultivate off-market opportunities, and contribute to portfolio strategy — not just fill the top of the funnel.

Davis's role reflects that evolution. He's not just sourcing deals; he's helping Shoreview decide which deals are worth pursuing in the first place. That requires a different skill set — one that blends investment judgment with interpersonal savvy and a willingness to spend time on opportunities that may not close for 18 months.

Healthcare private equity isn't monolithic. Some subsectors are overheated; others are just getting started. Understanding where the capital is flowing — and why — helps contextualize moves like Davis's promotion.

Behavioral health remains hot. Valuations for high-quality platforms routinely exceed 12x EBITDA, and competition for assets is fierce. But the sector still offers fragmentation, geographic expansion opportunities, and the potential for margin improvement through operational discipline. Firms that can source deals before they hit the broker market have a meaningful advantage.

Specialty care is another active area. Dermatology, ophthalmology, and gastroenterology roll-ups have attracted billions in capital over the past five years. The playbook is well-established: aggregate independent practices, implement centralized billing and admin, expand ancillary services, and drive same-store growth. The challenge is finding platforms that aren't already over-leveraged or over-priced.

Post-acute care — home health, hospice, skilled nursing — presents a different risk-return profile. Reimbursement is more heavily weighted toward government payers, labor costs are rising, and regulatory scrutiny is increasing. But for firms with operational expertise and a long-term view, the demographic tailwinds are undeniable. Shoreview's focus on founder-led, operationally intensive businesses positions it well in this space.

The middle market — typically defined as companies with $10 million to $100 million in revenue — offers a sweet spot for private equity in healthcare. Companies are large enough to have established operations, stable cash flow, and proven demand. But they're small enough that institutional capital can still move the needle on growth, professionalization, and geographic expansion.

These businesses also tend to be founder-owned or family-controlled, which means they haven't been through a PE process before. That creates opportunity for firms like Shoreview, which position themselves as long-term partners rather than financial engineers looking to flip assets in three years. It's a positioning that works — when the firm actually delivers on the promise.

As Principal, Davis will likely take on greater responsibility for leading deal execution, not just origination. That means managing due diligence, negotiating terms, and presenting investment memos to the investment committee. It also means deeper involvement in portfolio company strategy and add-on acquisition support — work that requires a different muscle than sourcing but is equally critical to returns.

For Shoreview, the promotion is part of a broader effort to maintain momentum in a competitive market. The firm has built a reputation for sector focus, operational value creation, and partnership-oriented deal structures. But reputation only matters if you can keep sourcing high-quality opportunities. That's where Davis comes in.

The next 18 months will be telling. If healthcare M&A activity picks up — and many expect it will as financing markets stabilize — Shoreview will need its business development team firing on all cylinders. If the market stays choppy, the firm's ability to source proprietary deals and avoid overpaying in auctions will matter even more.

Either way, promoting Davis now positions Shoreview to move quickly when opportunities arise. In private equity, timing isn't everything — but it's close.

Not all private equity firms have dedicated business development teams. Some rely on investment professionals to source their own deals. Others partner with intermediaries and focus on winning competitive processes. Shoreview's model — a standalone business development function with career progression — reflects a belief that origination is specialized work that deserves dedicated resources.

This approach has trade-offs. On the plus side, business development professionals can focus exclusively on relationship-building, market mapping, and thesis development without the distraction of portfolio management or fundraising. On the downside, it creates a potential divide between those who source deals and those who execute them — a dynamic that can lead to misaligned incentives if not managed carefully.

Shoreview's bet is that the benefits outweigh the risks — especially in healthcare, where sector expertise and long-term relationships with founders and management teams create defensible sourcing advantages. Davis's promotion reinforces that bet.

Other middle-market healthcare firms have made similar moves recently. Francisco Partners elevated a business development professional in its healthcare technology practice last year. Audax Group promoted two associates in its healthcare origination team in Q4 2024. The pattern is consistent: firms are investing in the infrastructure needed to source deals in a crowded, competitive market.

Here's the tension that no one in healthcare private equity wants to talk about publicly: the roll-up playbook has a shelf life. At some point, every fragmented subsector gets consolidated. Every independent practice either joins a platform or decides to stay small. Every add-on acquisition gets harder to justify at the multiples being paid.

Behavioral health isn't there yet. Neither is home health or certain specialty care verticals. But the clock is ticking. Firms that succeed in the next cycle won't just be good at sourcing and integrating acquisitions. They'll be good at building real operating capability, improving clinical outcomes, and driving organic growth — the stuff that's harder to engineer but ultimately more defensible.

Whether Shoreview — and professionals like Davis — can navigate that transition will determine whether the firm's healthcare bet pays off over the long term. For now, the focus is on deployment, deal flow, and getting the next platform right. But the strategic question looming in the background is already being asked by limited partners and, quietly, by the investment teams themselves.

Davis's promotion doesn't answer that question. But it does signal that Shoreview is playing the current game with conviction — and betting that the playbook still has room to run.